Kornimate/medical-research-clean huggingface dataset:
acl-r opioid sparing study

Conditions: Anterior Cruciate Ligament Injuries

Summary: this is a randomized control trial to investigate the effectiveness of a multimodal opiate sparing analgesic regimen in controlling post-operative pain and potentially reduce post-operative opioid consumption in patients undergoing anterior cruciate ligament reconstruction (acl-r).

there is increased attention on opioid prescription patterns and post-operative narcotic consumption in light of the ongoing opioid crisis in the united states. patients with opioid use disorders often have their first exposure to opioids following a medical or surgical procedure (shah et al., 2019). approximately 6% of patients who were opioid native preoperatively and received opioids postoperatively became long term users. as orthopedic surgeons account for approximately 8% of all dispensed opioid prescriptions (volkow et al., 2011), surgeons have investigated the effectiveness of multimodal analgesic regimens in controlling post-operative pain and reducing the amount of opioid consumption. recent studies have shown that an opiate sparing regimen consisted of nonsteroidal anti-inflammatory drugs can control post-operative pain adequately while reducing opioid consumption in patients who underwent arthroscopic knee or shoulder surgeries (gazendam et al., 2022; jones et al., 2022). currently, there is no clear consensus on pain management regimen after anterior cruciate ligament reconstruction. the purpose of this study is to 1) investigate the difference in pain score and opioid consumption among patients who receive the opioid-based protocol and those who receive opioid-sparing protocol; 2) minimize and potentially eliminate the utilization of narcotics following anterior cruciate ligament reconstruction (acl-r) surgery.

Eligibility criteria:
inclusion criteria: * 14-85 years of age. * patients undergoing primary acl-r with or without meniscus repair or meniscectomy, with or without chondroplasty. * patients weigh at least 90lbs at time of enrollment. * surgery scheduled at a campbell clinic surgery center (midtown or wolf river). * willing and able to provide written informed consent. * willing and able to cooperate with postoperative therapy. * speak and read fluent english. exclusion criteria: * multiligament knee reconstruction. * pre-injury opioid consumption. * substance abuse disorder (illicit drug abuse, alcoholism, etc). * concomitant injuries or surgeries warranting pain medication (i.e. polytrauma patient). * chronic pain syndrome. * renal disease. * currently taking selective serotonin reuptake inhibitors and/or serotonin and norepinephrine reuptake inhibitors. * known sensitivity, allergy, or intolerance to medications within protocols. * history of diabetes. * currently taking glucagon-like peptide 1 agonist. * female patient who is pregnant on day of surgery or becomes pregnant during study period.
investigation of endotracheal cuff pressure changes according to different positions in neurosurgery cases

Conditions: The Effect of Cuff Pressure on Postoperative Dysphagia

Summary: we aimed to measure the change in cuff pressure in different positions in neurosurgery cases and to investigate the effect of case length on cuff pressure.

it is an observational study, the cuffs of the endotracheal tubes of the patients who were intubated under general anesthesia between february 2023 and may 2023 will be inflated at 25 cm h2o pressure, and then the pressure line and the pilot balloon will be connected to the anesthesia monitor. the cuff pressure of the patient will be measured from the pilot balloon throughout the case and recorded at half-hour intervals. postoperative sore throat will be evaluated on the vas scale. postoperative cough, hoarseness, and dysphagia symptoms will be evaluated.

Eligibility criteria:
inclusion criteria: * neurosurgery patients between the ages of 18-70 ages * american society of anesthesiologist score i-ii-iii-iv exclusion criteria: * patients with previous tracheostomy * patients with tracheal stenosis * patients considered as difficult intubation * patients who have had more than one intubation attempt * patients with an asa score greater than 4 * patient who has difficulty understanding visual analog scale (vas) scores * language / communication barrier * patients younger than 18 years old

Keywords: cuff pressure postoperative dysphagia different positions in neurosurgery
validation of the french version of the primary lateral sclerosis functioning rating scale (plsfrs)

Conditions: Lateral Sclerosis

Summary: this is a national, multicentric, prospective, descriptive study evaluating the psychometric properties of the french version plsfrs scale

this is a prospective study conducted in 8 french als centers which will enroll 80 patients with pls. all these patients will undergo an evaluation of their functional status from the alsfrs-r and plsfrs scales. all patients will be evaluated at 3 time points (t0,m6 at the outpatient clinic) and at m3 remotely. the aim of the study will be to validate a trans-cultural and psychometric version of the plsfrs available for the french pls population.

Eligibility criteria:
inclusion criteria: * patients with primary lateral sclerosis (pls) * age over 18 years * informed consent signed * patients cared in a french als centre exclusion criteria: * patients with no oral and written command of the french language * patients unable to answer a questionnaire * opposition to data processing

Keywords: scale
epidemiologic data of patients in a teaching hospital

Conditions: Kidney Diseases; Obesity

Summary: this small cross-sectional epidemiological study is designed to evaluate the prevalence of the following parameters in hospitalized patients in a tertiary teaching hospital (medical department only): * kidney insufficiency * obesity * use of unfractionated heparins / low molecular weight heparins * other drugs effecting the hemostatic system

this small cross-sectional epidemiological study is designed to evaluate the prevalence of the following parameters in hospitalized patients in a tertiary teaching hospital (medical department only): * kidney insufficiency * obesity * use of unfractionated heparins / low molecular weight heparins * other drugs effecting the hemostatic system

Eligibility criteria:
inclusion criteria: * all patients hospitalized at the defined days (two days) at kantonsspital luzern, department of medicine

Keywords: low molecular weight heparin unfractionated heparin
percutaneous irreversible electroporation for unresectable hepatic carcinoma in poor liver function

Conditions: Hepatic Carcinoma

Summary: the purpose of this study is to investigate the safety and efficacy of irreversible electroporation for unresectable hepatic carcinoma in poor liver function, also progress free survival (pfs) and over survival (os) will be recorded.

hepatic carcinoma is the fifth most common cancer worldwide and a large proportion of patients are unsuitable for tumor resection because of factors such as poor hepatic reserve(cirrhosis) which directly lead a poor liver function. direct ablative treatments include radiofrequency ablation, microwave (mw) ablation and cryotherapy and irreversible electroporation had been used successful as a therapeutic choice for unresectable patients. at the same time，irreversible electroporation(ire)，which was applied with a novel ablation technology, can induce tissue necross by utilizing short pulses of high-voltage electrical energy. the technique also had many advantages, including short ablation time, preservation of vital structures within ire-ablated zone, avoidance of heat/cold-sink effect, complete ablation with well-demarcated margin and real-time monitoring of ire ablation.

Eligibility criteria:
inclusion criteria: * hepatic carcinoma diagnosed by positive biopsy or non-invasive criteria, * not suitable for surgical resection or transplantation, * have at least one, but less than or equal to 3 tumors, * of the tumour(s) identified, each tumor must be ≤ 5 cm in diameter, * child-pugh class b or ≤12， * eastern cooperative oncology group (ecog) score of 0-1, * american society of anaesthesiologists (asa) score ≤ 3, * a prothrombin time ratio \> 50%, * platelet count \> 80x109/l, * ability of patient to stop anticoagulant and anti-platelet therapy for seven days prior to and seven days post nanoknife procedure, * are able to comprehend and willing to sign the written informed consent form (icf), * have a life expectancy of at least 3 months. exclusion criteria: * eligible for surgical treatment or transplantation for hcc, * hepatic carcinoma developed on an already transplanted liver, * cardiac insufficiency, ongoing coronary artery disease or arrhythmia, * any active implanted device (eg pacemaker), * women who are pregnant or women of child-bearing potential who are not using an acceptable method of contraception, * have received treatment with an investigational agent/ procedure within 30 days prior to treatment with the nanoknife™ ledc system, are in the opinion of the investigator unable to comply with the visit schedule and protocol evaluations.
inflammation during ecmo therapy and ecmo weaning

Conditions: Acute Respiratory Distress Syndrome

Summary: the goal of this interventional clinical trial is to compare patients who undergo ecmo therapy for treatment of acute respiratory distress syndrome (ards) and a randomized into one of two possible weaning strategy groups. group 1: weaning from ventilator occurs before ecmo weaning. group 2: weaning from ecmo occurs before weaning from ventilator. this study investigates which one of these strategies is more indulgent for the lung, and leads to less inflammation and therefore less potential side effects and an overall more favourable clinical course. as a primary criterion, measure of il-6 in blood samples will beused. as secondary criterions, sofa score at various time points, ventilation pressures, lung injury score (lis), length of stay in the intensive care unit, and ventilator-associated pneumonia as well as levels of inflammatory cells and cytokines in both blood samples and bronchoalveolar lavage at different time points will be determined.


Eligibility criteria:
inclusion criteria: * acute respiratory distress syndrome (ards) according to the berlin definition (pao2/fio2 \< 100) and treatment with veno-venous ecmo (vvecmo) * hemodynamic stability * lung compliance did not change/improved during the last 24 hours * tidal volume did not change/improved during the last 24 hours with a peep of 10 cmh20 or above * consent of the patient or their legal representative exclusion criteria: * age \< 18 years * artificial ventilation for more than 7 days prior * patient, legal representative or doctors decided against an unrestricted intensive care treatment * positive pregnancy test at time of screening * cardiac failure requiring veno-arterial ecmo therapy * chronic respiratory insufficiency requiring long-term oxygen treatment

Keywords: acute respiratory distress syndrome extracorporal membrane oxygenation extracorporal membrane oxygenation weaning ventilation therapy
interval study: to determine whether the interval between blood donations in england can be safely and acceptably decreased

Conditions: Blood Donation

Summary: it is hypothesised that the number of donations made by english blood donors will be greater with reduced vs. standard inter-donation intervals. the null hypothesis is that there will be no difference in donations between treatment groups; this may arise if reduced inter-donation intervals result in a greater number of donation deferrals (due to low haemoglobin) and/or an unacceptable burden to donors.

50,000 blood donors will be recruited from permanent blood donation centres across england to compare different intervals between blood donations to try to find the optimum interval for which it is safe for different donors to give blood. the study will look at whether intervals should be tailored by age, gender, genetic profile, and other characteristics. study findings should help to improve the well-being of future blood donors in england and enhance the country's blood supplies.

Eligibility criteria:
inclusion criteria: 1. aged 18 years or older and fulfilling all normal criteria for blood donation 2. willing to be assigned to any of the study intervention groups 3. registered at one of the permanent donation clinics at the time of enrolment exclusion criteria: * as the aim of the study is to be almost "paper-less", it will involve remote web-based data collection. hence, participants who do not have internet access and/or are not willing to provide an email address for study correspondence will be excluded.

Keywords: rct blood donation frequency quality of life iron deficiency
the effects of supervised aerobic training on dyslipidemia among diabetic older patients

Conditions: Diabetes Mellitus; Exercise

Summary: in this study, we are trying to explore the potential effects of moderate aerobic exercise for six months on the severity values of blood sugar, hba1c, insulin, lipid profile, and highly sensitive crp (hs-crp) in a total of 50 subjects diagnosed with diabetes for more than five years with an age range of 30-70 years.

this study explored the influence of 6 months of moderate-intensity supervised aerobic training on diabetic control parameters, serum lipid profile, hs-crp, and variable-related correlations in prediabetic and type 2 diabetic patients (t2md). the patients were classified into two groups: the prediabetes group (hba1c ≤ 6.5, n = 25) and the t2md group (hba1c ≥ 6.5, n = 25). the values of blood sugar, hba1c, insulin, lipid profile, and highly sensitive crp (hs-crp) were measured in all subjects by using colorimetric and immunoassay techniques respectively at baseline and postintervention of moderate aerobic exercise for six months. participants performed the exercise test three times per week for 6 months. the training set comprised of a warming phase by stretching exercises and walking for 5 to 10 minutes, the participants were allowed to reach their precalculated training heart rate (thr) in bout form with a total time of 45 to 60 minutes performed as circuit training using a treadmill, bicycle, and stair master. all patient groups were subjected to estimate diabetic control parameters such as fbs, fi, hba1c, serum lipid profile, hs-crp, and bmi as anthropometric changes before and after moderate aerobic exercise training for six month

Eligibility criteria:
inclusion criteria: diagnosed with type 2 diabetes (dm2) for more than 5 years according to the american diabetes association criteria exclusion criteria: * patients with a history of smoking, abnormal alcohol intake, anemia, overt complications of diabetes like nephropathy, neuropathy, retinopathy, and other heart complications, and are suffering from viral infections, chronic liver disease, hypothyroidism, and drugs (diuretics; oral contraceptives) were excluded from this study
evaluation of neointimal coverage of ees and bms after implantation in stemi patients by optical coherence tomography

Conditions: Acute Myocardial Infarction

Summary: primary percutaneous coronary intervention (pci) represents the preferred reperfusion strategy for patients with st-segment elevation myocardial infarction (stemi), since it is more effective than thrombolytic regimens in reducing adverse events, including death. drug-eluting stents (des) are currently being widely used in patients with stemi. the effectiveness of des to reduce restenosis and the need for revascularization compared with bare-metal stents (bms) has been documented in randomized controlled trials. the first-generation dess implanted in stemi have been associated with delayed healing and incomplete strut coverage. therefore, in patients with implanted des, longer duration of dual antiplatelet therapy is needed. the second-generation dess (zes and ees) have been improved the drug and polymer, which have been proved to improve neointima healing compared with the first generation dess. however, the difference of strut coverage between ees and bms implanted in stemi patients is unknown. in this study, we assess the neointimal coverage at 3-month and 12-month follow-up in ees and bms implanted in patients with stemi by optical coherence tomography.


Eligibility criteria:
inclusion criteria: * age: 18-75 years * acute mi with st-segment elevation, within 12 hours from symptoms onset. * length of culprit lesion≤25mm. * vessel size in between 2.5 and 4.0 mm. * signed patient informed consent. exclusion criteria: * prior administration of thrombolytic therapy. * cardiogenic shock. * renal failure (crea≥2.0mg/dl). * recent major bleeding. * allergy to heparin, aspirin, clopidogrel, everolimus, the polymer components of the xience v stent, stainless steel, or contrast media. * left main disease * multi-vessel lesion * other hemodynamically significant lesion(s) is present in the infarct vessel (or side branches) * angiography demonstrates the infarct lesion to be at the site of a previously implanted stent or in bypass grafts. * no suitable anatomy for oct scan.

Keywords: acute myocardiac infarction bare-metal stent everolimus-eluting stent optical coherence tomography
assessment of endocan serum levels in patients with behcet disease

Conditions: Behçet

Summary: the aim of our study was to assess serum endocan levels in patients with behcet disease and to correlate it with various disease clinical and laboratory parameters of disease activity as well as carotid intima media thickness.

this study will be carried out on two groups: • group (i): forty two patients diagnosed to have behcets disease fulfilling the international criteria for bd . group (ii): including 42 age and sex matching healthy volunteers as control group. (a) clinical evaluation 1. complete history taking. 2. thorough clinical examination including opthalmologic evaluation . 3. disease activity using the behcet's disease current activity form (bd-daf) . (b) laboratory assessment: all patients will be subjected to the following measurements: 1. esr 2. crp 3. cbc 4. liver and kidney function tests d) serum endocan level e)triglycrides f) cholestrol c) carotid intima media thickness

Eligibility criteria:
inclusion criteria: * patients with behcets disease fulfilling the international criteria for bd . exclusion criteria: * infection * malignancy * other connective tissue disease * chronic liver disease * chronic kidney disease * diabetes mellitus * hypertension * hyperlipidemia

Keywords: behçet disease endocan
study of efficacy and safety of canakinumab in japanese patients with aosd

Conditions: Adult Onset Still's Disease

Summary: this is a phase iii study designed to provide efficacy and safety data for canakinumab administered for at least 48 weeks as subcutaneous (s.c.) injection every 4 weeks (q4wk) in japanese patients with adult onset still's disease (aosd). interim analysis (ia) data at week 28 and 48 from this study supports a registration submission of canakinumab in the indication of adult still's disease (asd) in japan.


Eligibility criteria:
inclusion criteria: * signed informed consent must be obtained prior to participation in the study. parent's or legal guardian's written informed consent and child's assent, if appropriate, are required before any assessment is performed for participants \< 20 years of age * japanese male and female participants aged ≥ 16 years * confirmed diagnosis of aosd as per yamaguchi criteria (yamaguchi m, 1992) with an onset of disease ≥ 16 years of age. yamaguchi criteria requires at least five criteria, including two major criteria and no exclusion criteria * active disease at the time of baseline defined as follows * fever (body temperature \> 38°c) due to aosd for at least 1 day within 1 week before baseline * at least 2 active joints (tender or swollen) * crp ≥ 10 mg/l exclusion criteria: * pregnant or nursing (lactating) female participants, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hcg laboratory test (\> 5 miu/ ml) at screening visit. * history of significant hypersensitivity to study drug or to biologics. * history/evidence of active macrophage activation syndrome or disseminated intravascular coagulation prior to 6 months of enrollment. * with underlying metabolic, renal, hepatic, infectious or gastrointestinal conditions which in the opinion of the investigator compromises the articipant and/ or places the participant at unacceptable risk for participation in an immunomodulatory therapy. * with active or recurrent bacterial, fungal or viral infection at the time of enrollment, including participants with evidence of human immunodeficiency virus (hiv) infection, hepatitis b and hepatitis c infection. * participants with absolute neutrophil count \< 1500/mm3 at screening.

Keywords: canakinumab aosd il-1β japanese participants
micro-mobile foot compression and diabetic foot

Conditions: Diabetes; PAD; Lower Extremity Edema; Neuropathy;Peripheral; Foot Ulcer, Diabetic; Lymphatic Diseases

Summary: diabetic foot ulceration (dfu) is a common and largely preventable complication. while most of these ulcers can be treated successfully, some will persist and become infected. ultimately, nearly one fifth of patients with infected lower-extremity diabetic ulcers will require amputation of the affected limb.prevention by identifying people at higher risk is the key for better clinical management of such patients. it is not uncommon for patients suffering from diabetes to have concomitant lower extremity edema or even venous insufficiency and they subsequently may benefit from graduated compression. however, because of the common association of peripheral arterial disease (pad) in patients with diabetes, most clinicians are reluctant to apply compressive dressings in fear of exacerbating the symptoms of pad and the possible resulting gangrene. a novel micro-mobile foot compression device named footbeat (avex, inc.) offers alternative means providing lower extremity compression. this device is portable and can be used in a standard diabetic shoes on daily basis, which in turn may improve venous blood and relief from concomitant lower extremity edema. in addition, potential improvement in lower extremity blood flow in response to regular foot compression, could improve balance, gait, skin perfusion, plantar sensation, and overall daily physical activities (e.g. number of taken steps per day, duration of standing, etc). the purpose of this study is to conduct an observational study with n=30 ambulatory patients with diabetes and loss of protective sensation to assess whether this micro-mobile foot compression device can help improving motor function, lower extremity perfusion, and vascular health.


Eligibility criteria:
inclusion criteria: * male or female , age 18 or older with the ability and willingness to provide informed consent * patient is willing to participate in all procedures and follow up evaluations necessary to complete the study * history of type 2 diabetes confirmed by patient's physician. * history of peripheral neurpathy . exclusion criteria: * patients with severe peripheral vascular disease (ankle-brachial systolic pressure index (abi) \ 1.30) * patients with active wound infection, or untreated osteomyelitis * patients with major foot deformities (e.g. charcot foot) or major amputation (e.g. above ankle) * unamulatory of those who are unable to independently walk with or without walking assistance, a distance of 40 feet. * patients who are unable or unwilling to participate in all procedures and follow up evaluations * patients currently on immunosuppressive drugs. * pregnant or breast feeding ladies.